Display options
Cite
Mapelli SN, Albino D, Mello-Grand M, et al. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers (Basel). 2020;12(1)doi: 10.3390/cancers12010176.
Mapelli, S. N., Albino, D., Mello-Grand, M., Shinde, D., Scimeca, M., Bonfiglio, R., Bonanno, E., Chiorino, G., Garcia-Escudero, R., Catapano, C. V., & Carbone, G. M. (2020). A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers, 12(1), . https://doi.org/10.3390/cancers12010176
Mapelli, Sarah N, et al. "A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors)." Cancers vol. 12,1 (2020). doi: https://doi.org/10.3390/cancers12010176
Mapelli SN, Albino D, Mello-Grand M, Shinde D, Scimeca M, Bonfiglio R, Bonanno E, Chiorino G, Garcia-Escudero R, Catapano CV, Carbone GM. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers (Basel). 2020 Jan 10;12(1). doi: 10.3390/cancers12010176. PMID: 31936761; PMCID: PMC7016595.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Jan 10;12(1). doi: 10.3390/cancers12010176.

A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors).

Cancers

Sarah N Mapelli, Domenico Albino, Maurizia Mello-Grand, Dheeraj Shinde, Manuel Scimeca, Rita Bonfiglio, Elena Bonanno, Giovanna Chiorino, Ramon Garcia-Escudero, Carlo V Catapano, Giuseppina M Carbone

Affiliations

  1. Institute of Oncology Research (IOR), Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland.
  2. Swiss Institute of Bioinformatics (SIB), 1015 Lausanne, Switzerland.
  3. Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, 13900 Biella, Italy.
  4. Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.
  5. Molecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
  6. Biomedicine Research Institute, Hospital 12 octubre, 28040 Madrid, Spain.
  7. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28040 Madrid, Spain.
  8. Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, 1011 Lausanne, Switzerland.

PMID: 31936761 PMCID: PMC7016595 DOI: 10.3390/cancers12010176

Abstract

In this study, we extracted prostate cell-specific gene sets (metagenes) to define the epithelial differentiation status of prostate cancers and, using a deconvolution-based strategy, interrogated thousands of primary and metastatic tumors in public gene profiling datasets. We identified a subgroup of primary prostate tumors with low luminal epithelial enrichment (LumE

Keywords: gene classifier; gene signature; predictive biomarkers; prostate cancer; tumor classification

References

  1. Nat Med. 2016 Apr;22(4):369-78 - PubMed
  2. Nature. 2009 Sep 24;461(7263):495-500 - PubMed
  3. Cancer Cell. 2010 Jan 19;17(1):98-110 - PubMed
  4. Cancer Cell. 2010 Jul 13;18(1):11-22 - PubMed
  5. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6823-34 - PubMed
  6. Front Oncol. 2015 Jan 12;4:375 - PubMed
  7. Mol Cancer Res. 2019 Nov;17(11):2154-2168 - PubMed
  8. Eur Urol. 2005 Jun;47(6):895-900 - PubMed
  9. JAMA Oncol. 2017 Dec 1;3(12):1663-1672 - PubMed
  10. Science. 2018 Oct 5;362(6410):91-95 - PubMed
  11. Cold Spring Harb Perspect Med. 2019 Jun 3;9(6): - PubMed
  12. Nat Commun. 2013;4:2612 - PubMed
  13. Nat Rev Cancer. 2015 Sep;15(9):563-72 - PubMed
  14. J Natl Cancer Inst. 2008 Jun 4;100(11):815-25 - PubMed
  15. Cell. 2015 May 21;161(5):1215-1228 - PubMed
  16. Cancer Cell. 2012 Feb 14;21(2):253-65 - PubMed
  17. Nat Rev Urol. 2018 May;15(5):271-286 - PubMed
  18. Nat Rev Clin Oncol. 2014 Jun;11(6):308-23 - PubMed
  19. BMC Genomics. 2006 Apr 25;7:92 - PubMed
  20. Eur Urol. 2017 Oct;72(4):509-518 - PubMed
  21. CA Cancer J Clin. 2018 Jan;68(1):7-30 - PubMed
  22. Elife. 2015 Sep 16;4: - PubMed
  23. Science. 2010 Jul 30;329(5991):568-71 - PubMed
  24. EMBO J. 2011 May 20;30(13):2719-33 - PubMed
  25. Brief Bioinform. 2017 May 1;18(3):426-440 - PubMed
  26. Curr Protoc Pharmacol. 2018 Jun;81(1):e39 - PubMed
  27. Urol Oncol. 2019 May;37(5):297.e19-297.e31 - PubMed
  28. Cancer Cell. 2014 May 12;25(5):638-651 - PubMed
  29. Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 - PubMed
  30. Mol Cell Endocrinol. 2018 Apr 15;465:73-81 - PubMed
  31. Cancer Discov. 2019 Jun;9(6):702-710 - PubMed
  32. Nature. 2012 Jul 12;487(7406):239-43 - PubMed
  33. Cancer Res. 2016 Sep 1;76(17):4948-58 - PubMed
  34. Science. 2017 Oct 20;358(6361):321-326 - PubMed
  35. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  36. Nature. 2009 Nov 5;462(7269):108-12 - PubMed
  37. Cell Death Dis. 2018 Feb 5;9(2):155 - PubMed
  38. Cancer Res. 2011 Oct 15;71(20):6503-13 - PubMed
  39. Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6544-52 - PubMed
  40. Nat Med. 2016 Mar;22(3):298-305 - PubMed

Publication Types

Grant support